Akebia Therapeutics (AKBA) Gains from Investment Securities (2017 - 2026)

Akebia Therapeutics (AKBA) has 4 years of Gains from Investment Securities data on file, last reported at -$456000.0 in Q1 2026.

• On a quarterly basis, Gains from Investment Securities fell 194.19% year-over-year to -$456000.0 in Q1 2026; TTM through Mar 2026 was $2.8 million, a 6117.78% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 839.09% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$456000.0, up from -$2.3 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for AKBA reached as high as $7.0 million in Q2 2025 and fell as low as -$2.3 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged $330222.2 across 3 years, with a median of -$155000.0 in 2025.
• On a YoY basis, Gains from Investment Securities climbed as much as 399.44% in 2025 and fell as far as 271.03% in 2025.
• Year by year, Gains from Investment Securities stood at $1.7 million in 2024, then plunged by 235.04% to -$2.3 million in 2025, then surged by 79.84% to -$456000.0 in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$456000.0 in Q1 2026, -$2.3 million in Q4 2025, and -$1.5 million in Q3 2025.